Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1274)	5/13/2003 8:12:12 AM
From: Icebrg	Read Replies (1) \| Respond to of 1321

I made some comments after having listened to the CC. Unfortunately the posting was done on the wrong thread and even if it had been the right thread, I was not supposed to have posted any comments over there. So, as a feeble attempt at some recycling, I am offering the following link. Message 18938464 Having said and done that, I would also like to ask about Visudyne. Genentech has recently made a lot of positive noices about a mAb-fragent which they have under development. rhuFab is a part of their Avastin mAb and is supposed to treat the wet form of age-related macular degeneration. The folks at Genentech seem to be pretty excited about this product and are really speeding it through the clinics. Is this not a potential competitor to Visudyne? Erik